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Dr Roy M. Fujitani (Orange, Calif). As a consequence of the
Fistula First Project which was launched in 2003, the United States
ESRD Networks have experienced an increase in the prevalent con-
struction and use of autologous arteriovenous fistulas (AVFs). The
National Kidney Foundation’s Kidney Disease Outcomes Quality
Initiative (NKF/K-DOQI) guidelines for vascular access in 2006 had
recommended a 66% prevalent AVF rate. This goal still remains lower
than the reported rates of AVF construction in Japan or Europe, but
the U.S. rates continue to increase. The more recent U.S. Renal Data
System Healthy People 2020 (HP 2020) have set a target 50.6%Meanwhile, the worldwide incidence and prevalence of end
tage renal disease (ESRD) continues to rise at an exponential rate.
oreover, racial and ethnic discrepancies in ESRD persist, with
frican Americans having a 3.6 times greater rate than whites. Yet,
any series have demonstrated a disparity in the number of autog-
nous AVFs used in the incident ESRD population among racial
nd gender groups. Despite these recognized difference in incident
se of autogenous AVFs, the exact reasons for these discrepancies
emain unclear. The authors here sought to determine (1) whether
here were racial differences in AVF creation, (2) whether this may
e related to differences in vein diameters, and (3) whether AVF
atency rates are similar between black and non-black patients.
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August 2012432 Ishaque et alDespite the retrospective nature of this report, the thorough-
ness of the data points is remarkable. The population studied
included consecutive male patients treated at two institutions,
including a Veteran’s Affairs Hospital and a University Medical
Center, receiving incident vascular access over a 4.5-year period.
They report a significant discrepancy in vein size on preoperative
vein mapping between black and non-black patients, with signifi-
cantly smaller basilic veins and smaller cephalic veins in the distal
upper arm and proximal forearm in the black cohort. The authors
report an 89% rate of AVF construction of the total 249 patients
reviewed, using a 2.5-mm standardized threshold for using autog-
enous vein. In the subgroup of 95 black patients, 82% had autog-
enous AVFs constructed, compared to 93% in the non-white
patient cohort. The 1-year primary patency of 81%, primary func-
tional patency of 73%, and secondary functional patency of 91% in
the incident black population is quite notable.
I have several general questions for the authors:
Environmental factors, including the ambient room tempera-
ture, may affect the vasoreactivity of veins during ultrasound vein
mapping. The use of proximal tourniquets may also change vein
diameters substantially. You describe taking measurements at four
locations on the upper limbs including the proximal and distal
upper arm and proximal and distal forearm. Besides diameter
measurements, have you looked at qualitative features of the vein
along its entire length, including compressibility, wall thickness,
and distensibility? Were all source images reviewed by more than
one reviewer, or were measurements gleaned off the published
ultrasound reports?
Dr Christian de Virgilio. We agree with Dr Fujitani that
qualitative features of the vein are important.We have certainly had
the unfortunate experience of having what appears to be a good
diameter vein on preoperative ultrasound, only to discover intra-
operatively that the vein has sclerosis and is not distensible. How-
ever, in this retrospective study, vein diameter measurements were
simply obtained from the published ultrasound reports that were
available on the electronic records.
Dr Fujitani. You note that you used a 2.5-mm threshold for
autogenous fistula construction. Although the median vein diam-
eter at the distal forearm measured 2.3 mm in black patients, you
report that 41% of the black patients (which accounts for the
majority) had a radiocephalic fistula constructed. This would imply
that one-half of these black patients had autogenous fistula con-
structed with veins2.3 mm. Was 2.5 mm really the threshold? If
a
lot, what other factors contributed to the decision making process
n using the vein?
Dr de Virgilio. The ultimate decision as to whether to create
fistula was at the discretion of the operating surgeon. We do not
se an absolute cutoff of 2.5 mm based on preoperative ultra-
ound. Rather, our general policy is that if the cephalic vein
pproximates 2.5 mm, we will explore the vein intraoperatively.
fter dividing the vein distally, we gently dilate it with a dilute
apaverine solution. If the vein is distensible, we then make a
ne-time pass with a 2.5 mm coronary dilator. If the dilator does
ot easily pass, we abandon the site and move to the elbow. We do
ot attempt to use the dilator to dilate the vein.
Dr Fujitani. Several clinical series have demonstrated a ten-
ency toward a higher incidence of failure of fistula maturation
hen taking a very aggressive approach to autogenous fistula
onstruction. Yet with 82% of black patients and 93% of non-black
atients having autogenous fistula constructed, only 8.4% and
.3%, respectively, failed to mature. How do you account for your
ery remarkable outcomes with an aggressive “Fistula First” ap-
roach?
Dr de Virgilio. We feel that our results reflect multiple
actors. First, we feel that careful patient selection, in terms of
hoosing the right fistula, is vital. A key element, as just mentioned,
s determining whether the cephalic vein at the wrist distends with
apaverine. In addition, by passing a coronary dilator up the vein,
e occasionally encounter vein stenoses from prior intravenous
ines that would not otherwise have been detected by preoperative
ltrasound. At the end of the procedure, we insist on palpating an
mmediate thrill, rather than hoping that a thrill will develop later.
e do not hesitate to shift to an elbow fistula if any of these issues
re encountered. Cephalic vein tributaries in the forearm are
dentified at the initial surgery and preemptively ligated. When
reating a brachial-basilic fistula, we have shifted to the two-stage
pproach. We previously found that the two-stage brachial-basilic
stula is associated with a significantly greater patency. Finally, we
sed to only see these patients once postoperatively and then sent
he patients back to the nephrologist to allow them to determine
hen to cannulate the fistula. Now, we see patients at least twice
ostoperatively, at 1 week and at 6 weeks. If at 6 weeks the fistula
oes not appear to be maturing, is less than 6 mm in diameter, or
s deeper than 6 mm from the skin, we will take an aggressive
pproach to investigate the problem via duplex scan and/or fistu-
agram.
